PDX-Derived Melanoma Organoid Model

Malignant melanoma is triggered by somatic mutation, whose incidence increasingly rises in recent years. BRAF inhibitors (BRAFi), as the standard treatment of melanoma, effectively promote the response rate of patients. However, it fails to prevent most recurrent and progression issues resulting from drug resistance after about six months. Therefore, it is a consensus that new drug strategies should be developed to rescue patients from the threat of malignant melanoma. At Creative Biolabs, we have a rich-experienced research team to study new 3D modeling technologies such as PDX-derived melanoma organoids to respond to your drug development needs.

Shortcomings of Common Models

For melanoma research, there are multiple types of models available to choose from, but they show shortcomings in practical applications. For example, 2D cell culture lack of heterogeneity and can not fully reflect tumor behavior in vivo due to growth on the cell-cultured plate. In addition, genetic drift often happens in the long-term passage and will lead to high variability and poor reproducibility of the results. Regarding genetically engineered mouse models (GEMMs), the distinct drawback is the inability to reflect the mutational burden found in human patient tumors. Again, for instance, the patient-derived xenografts (PDXs) heavily rely on the immunocompromised or immunodeficient mouse, which poses a tough challenge to investigating the drug resistance mechanisms.

Advantages of PDX-derived Organoid Models

Opposed to the aforementioned models, the PDX-derived melanoma organoids deal with the concerning limitations and enhance the clinical translational potential as a preclinical model. Given their unique advantages, it is undoubtedly that such models will bring more breakthrough progress in the melanoma field. Here, we simply overview their advantages for your reference so that you can decide whether it is suitable for your project.

• They allow us to describe the cellular heterogeneity and plasticity of melanoma cells.
• This kind of model contains different cell lines, which provides a helpful condition for an investigation into how the treatment strategies may influence the immune system.
• They are appropriate for the high-throughput technology to test the efficacy of single-agent or combination therapies.
• The establishment of the PDX-derived organoid models needs only a few samples.

Applications

In summary, PDX organoids have more excellent performance compared with PDXs and patient-derived organoids (PDOs) alone. By combining with some novel technologies, such as real-time imaging and 3D printing, they will promote rapid progress in melanoma drug discovery and help improve the success rate of clinical translation.

Fig.1 Applications of PDX-derived melanoma organoid models. (Creative Biolabs)

Related Services

As a leading biotech company, Creative Biolabs has established an advanced 3D biology platform to provide ex vivo physiological models, including 3D organoid models, for worldwide customers. We serve every customer sincerely and try our best to meet each clientt’s requirement to conduct tumor biological research. We are always ready to offer high-quality PDX-derived melanoma organoid models and related services listed below to accelerate your preclinical drug research progress. For more details, please feel free to contact us.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model